Skip to main content
Intended for healthcare professionals
Free access
Research article
First published online July 2, 2013

Serrapeptase and nattokinase intervention for relieving Alzheimer’s disease pathophysiology in rat model

NN Fadl, HH Ahmed [email protected], HF Booles, and AH SayedView all authors and affiliations
All Articles
https://doi.org/10.1177/0960327112467040

Abstract

Serrapeptase (SP) and nattokinase (NK) are proteolytic enzymes belonging to serine proteases. In this study, we hypothesized that SP and NK could modulate certain factors that are associated with Alzheimer’s disease (AD) pathophysiology in the experimental model. Oral administration of aluminium chloride (AlCl3) in a dose of 17 mg/kg body weight (bw) daily for 45 days induced AD-like pathology in male rats with a significant increase in brain acetylcholinesterase (AchE) activity, transforming growth factor β (TGF-β), Fas and interleukin-6 (IL-6) levels. Meanwhile, AlCl3 supplementation produced significant decrease in brain-derived neurotrophic factor (BDNF) and insulin-like growth factor-1 (IGF-1) when compared with control values. Also, AlCl3 administration caused significant decline in the expression levels of disintegrin and metalloproteinase domain 9 (ADAM9) and a disintegrin and metalloproteinase domain 10 (ADAM10) genes in the brain. Histological investigation of brain tissue of rat model of AD showed neuronal degeneration in the hippocampus and focal hyalinosis with cellular as well as a cellular amyloid plaques formation. Oral administration of SP or NK in a rat model of AD daily for 45 days resulted in a significant decrease in brain AchE activity, TGF-β, Fas and IL-6 levels. Also, the treatment with these enzymes produced significant increase in BDNF and IGF-1 levels when compared with the untreated AD-induced rats. Moreover, both SP and NK could markedly increase the expression levels of ADAM9 and ADAM10 genes in the brain tissue of the treated rats. These findings were well confirmed by the histological examination of the brain tissue of the treated rats. The present results support our hypothesis that the oral administration of proteolytitc enzymes, SP and/or NK, would have an effective role in modulating certain factors characterizing AD. Thus, these enzymes may have a therapeutic application in the treatment of AD.

Introduction

In humans, Alzheimer’s disease (AD) develops over many years and it comprises a chain of subtle alterations in brain function, finally leading to the impairment of memory and cognition.1 The cognitive disability includes the impairment of behaviour, visual-spatial skills, speech and motor ability, depression, delusions, hallucinations, aggressive behaviour and ultimately, increasing dependence upon others before death.2 Genetic and neuropathological evidence suggests that the accumulation of amyloid-β (Aβ) peptides in the brain is a key event in the pathophysiology of AD. Amyloid fibrils are an ordered protein aggregate with a lamellar cross-beta structure. Enhancing amyloid clearance is one of the targets of the therapy of AD.3 Therefore, the therapeutic potential of several approaches aimed at lowering the level of Aβ in the brain is currently being investigated.4
Proteases are ubiquitous enzymes that are crucial for cell growth, development, apoptosis, protein turnover and cell cycle regulation during life process.5 Several serine proteases have been well characterized in the brain. Accumulating evidence demonstrates that some serine proteases play very important roles in the neural development, plasticity and neuroregeneration in the brain.6 The basis of these functions is the unique correct three-dimensional structures of the proteins, and all the information necessary for proteolysis are encoded by the amino acid sequence of protease.7 Diseases such as cystic and even some forms of cancer are believed to result due to defective protein folding.8
Serrapeptase (SP) is a proteolytic enzyme belonging to serine proteases. It is derived from the non-pathogenic enterobacteria Serratia E15. It is produced in the intestines of silkworms to break down cocoon walls. It has an anti-inflammatory effect.9 This enzyme is believed to induce the degradation of insoluble protein products like fibrin, biofilm and inflammatory mediators.10 Therefore, SP has also been used for the treatment of a number of inflammatory conditions.11,12
Nattokinase (NK), a bacterial serine protease derived from Bacillus subtilis, has been reported to have potent fibrinolytic activity.13 It is considered to be one of the most active functional ingredients found in natto, a traditional Japanese food prepared from the fermented soybeans.14 This enzyme is reported to directly digest fibrin especially in its cross-linked form.15 It has a fourfold greater thrombus-dissolving activity than plasmin and is shown to potentiate endogenous fibrinolysis by cleavage and to inactivate plasminogen activator inhibitor 1 (PAI-1),16 leading to efficient lysis of the detrimental coagulation of blood in the body.15 NK not only dissolves blood clots17 but also degrades amyloid fibrils.3
In this study, we hypothesized that SP and NK could correct certain factors including proteins, growth factors, apoptotic factor, inflammatory factor and genes that are associated with AD pathophysiology in the experimental model. To test this hypothesis, we investigated the effects of SP and NK on brain cholinesterase activity, brain-derived neurotrophic factor (BDNF), transforming growth factor β (TGF-β), insulin-like growth factor-1 (IGF-1), Fas and interleukin-6 (IL-6) levels. The study was extended to examine the effects of these enzymes on the expression levels of disintegrin and metalloproteinase domain 9 (ADAM9) and disintegrin and metalloproteinase domain 10 (ADAM10) genes. Histological investigation of brain tissue was also carried out to confirm the biochemical and molecular genetics observations.

Materials and methods

Aluminium chloride (AlCl3) was purchased from Sigma Co. (California, USA). Its molecular weight is 133.34.
The two proteolytic enzymes, SP (Doctors Best Serrapeptase 40,000 serratio units per veggie cap.) and NK (Doctors BEST Nattokinase 2000 FUs per veggie cap) were purchased from a dietary supplement market in USA.
Reagents for real time-polymerase chain reaction (RT-PCR) were purchased from Invitrogen (Carlsbad, USA) and Fermentas (Leon-Rot, Germany).
The human doses of the two proteolytic enzymes used were converted into rat equivalents with the help of conversion table described by Paget and Barnes.18
A total of 66 adult male albino rats weighing 120–150 g were enrolled in the current study. The rats were obtained from the Animal House Colony of the National Research Centre, Cairo, Egypt. The animals were housed in polypropylene cages in an environmentally controlled clean air room with a temperature of 24 ± 1°C, an alternating 12 h light–dark cycle, a relative humidity of 60 ± 5% and free access to tap water and food. Rats were allowed to adapt to these conditions for 2 weeks before beginning the experimental protocol. The animal experimental protocol has been approved by the Institutional Animal Ethics Committee of Medical Research, National Research Centre, Egypt. AD-like pathology model was achieved in rats by the oral administration of AlCl3 in a dose of 17 mg/kg bw19 daily for 45 days. The animals used in the present study were classified into six groups; G1: healthy control group (negative control); G2: AD group (positive control); G3: AD group treated orally with water suspension of SP in a dose of 10.8 U/kg bw daily for 45 days; G4: AD group treated orally with water suspension of SP in a dose of 21.6 U/kg bw daily for 45 days; G5: AD group treated orally with the water suspension of NK in a dose of 360 FU/kg bw daily for 45 days and G6: AD group treated orally with water suspension of NK in a dose of 720 FU/kg bw for 45 days daily.
At the end of the experimental period, the animals were fasted overnight, sacrificed by decapitation under diethylether anaesthesia. The whole brain of each rat was rapidly and carefully dissected, thoroughly washed with isotonic saline, dried on a filter paper and weighed. The whole brain of a certain number of animals in each group was fixed in formalin buffer (10%) for 24 h for histological examination and the whole brain of the rest number of animals in each group was mid-sagitally divided into two portions; the first portion was immediately stored in liquid nitrogen for gene expression analysis, while the second portion of the brain was weighed and homogenized immediately to give 10% (w/v) homogenate in ice-cold medium containing 50 mM Tris-HCl (pH 7.4) and 300 mM sucrose.20 The homogenate was centrifuged at 1800g for 10 min in a cooling centrifuge at 4°C. The supernatant (10%) was stored at −80°C till further analysis to assess cholinesterase activity, BDNF, TGF-β, IGF-1, Fas as well as IL-6 levels.

Biochemical analyses

Brain cholinesterase activity was determined kinetically using a kit purchased from Biostc Co (Cairo, Egypt), according to the method of Young.21 While, brain BDNF level was assayed by enzyme linked immunosorbent assay (ELISA) technique using kit purchased from RayBiotech, Inc. (Norcross, USA), according to the method described by Barde.22 Brain TGF-β and IGF-1 levels were determined by ELISA technique using a kit purchased from DRG instrument GmbH (Marburg, Germany), according to the methods described by Kropf et al.23 and Lewitt et al.24 respectively. Meanwhile, brain Fas level was detected by the ELISA technique using kit purchased from Diaclone a Tepnel Co. (France), according to the method described by Iio et al.25 Finally, brain IL-6 level was assayed by ELISA technique using kit purchased from RayBiotech, Inc, according to the method of Bauer and Herrmann.26 Quantitative estimation of total protein content in the brain was carried out according to the method of Lowry et al.27 to express the concentration of different brain parameter per milligram protein.28

Gene expression analysis

RNA extraction

Brain tissues of rats in each group were used to extract the total RNA. Total RNA was isolated from 100 mg of tissue by the standard TRIzol extraction method (Invitrogen, USA) and recovered in 100 μl molecular biology grade water. In order to remove any possible genomic DNA contamination, the total RNA samples were treated by DNA-free™ DNase and removal reagents kit (Ambion, Austin, Texas, USA) following the manufacturer’s protocol. The RNA concentration was determined by spectrophotometric absorption at 260 nm.

First-strand cDNA synthesis

To synthesize the first-strand complementary DNA (cDNA), 5 µg of the complete poly(A)+ RNA isolated from rat brain tissue was reverse transcribed into cDNA in a total volume of 20 µl using 1 µl oligo (poly(deoxythymidine)18) primer.29 The composition of the reaction mixture was 50 mM MgCl2, 10X reverse transcription (RT) buffer (50 mM KCl; 10 mM Tris-HCl; PH 8.3), 200 U/µl reverse transcriptase (RNase H free), 10 mM of each dNTP and 50 µM of oligo (dT) primer. The mixture of each sample was centrifuged for 30 s at 1000g and transferred into the thermocycler (Biometra GmbH, Göttingen, Germany). The RT reaction was carried out at 25°C for 10 min, followed by 1 h at 42°C, and finished with denaturation step at 99°C for 5 min. Later, the reaction tubes containing RT preparations were flash-cooled in an ice chamber until being used for DNA amplification through RT-PCR.30

RT-PCR assay

The first strand cDNA from each brain sample was used as a template for the semi-quantitative RT-PCR with a pair of specific primer in a 25-µl reaction volume. The sequences of specific primer and product sizes are listed in Table 1. β-Actin was used as a housekeeping gene for normalizing messenger RNA levels of the target genes. The reaction mixture for RT-PCR consisted of 10 mM dNTP’s, 50 mM MgCl2, 10X PCR buffer (50 mM KCl; 20 mM Tris-HCl; pH 8.3), 1 U/µl Taq polymerase and autoclaved water. The PCR-cycling parameters of the studied genes (ADAM9, ADAM10 and β-actin) were performed as the PCR condition summarized in Table 1. The PCR products were then loaded onto 2.0% agarose gel, along with the PCR products derived from β-actin of the different rat samples. Each reaction of the RT-PCR was repeated with the samples obtained from eight rats, generating new cDNA products at least eight times per each group.
Table 1. Primers and PCR-thermocycling parameters
Gene Primer sequence (5′-3′) Conditions of the PCR assay PCR amplicons (bp)
ADAM9 TGA CCA TCC CAA CGT ACA GA 35 cycles: 94°C for 40 s; 55°C for 40 s; 72°C for 45 s 316
  TTC CAA AAC TGG CAT TCT C Final extension: 72°C for 5 min  
ADAM10 TCT CCG GAA TCC GTA ACA T 40 cycles: 94°C for 30 s; 60°C for 30 s; 70°C for 1 min 600
  TCC AGG AAC TTC TCC ACA C Final extension: 68°C for 2 min  
Beta-Actin TTG CCG ACA GGA TGC AGA A 25 cycles: 94°C for 30 s; 65°C for 30 s; 72°C for 1 min 540
  GCC GAT CCA CAC GGA GTA CT Final extension: 75°C for 2 min  
PCR: polymerase chain reaction; ADAM9: disintegrin and metalloproteinase domain 9; ADAM10: disintegrin and metalloproteinase domain 10.

Histological investigation

Brain tissues previously fixed in formalin buffer (10%) for 24 h were washed under tap water for 20 min. Then, the serial dilutions of alcohol (methyl, ethyl and absolute ethyl) were used for dehydration. Specimens were cleared in xylene and embedded in paraffin at 56°C in hot air oven for 24 h. Paraffin beeswax tissue blocks were prepared for sectioning at 4-µm-thick using slidge microtome. The obtained tissue sections were collected on glass slides, deparaffinized and stained by hematoxylin and eosin stains31 for histological examination through the light microscope.

Statistical analysis

The results were expressed as mean ± SE. Data were analyzed by one-way analysis of variance and were performed using the Statistical Package for the Social Science (SPSS) program, version 11 followed by least significant difference to compare the significance between groups.32 Difference was considered significant at p < 0.05.

Results

Biochemical results

The data in Table 2 showed the effect of treatment with SP and NK on brain cholinesterase activity in the model of AD. The untreated AD group rats showed significant increase in brain cholinesterase activity in comparison with the negative control group. In contrast, the groups of AD group treated with low or high dose of SP (10.800 or 21.600 U/kg bw) or NK (360 or 720 Fu/kg bw) showed significant decrease in brain cholinesterase activity in comparison with the untreated AD group.
Table 2. Effect of treatment with SP and NK on brain cholinesterase activity in the model of ADa
Parameter Groups Cholinesterase (U/mg protein)
Negative control 591.6 ± 35.4
AD group (positive control) 770.8 ± 13.7a
AD+ SP (10.800 U/Kg bw) 680.4 ± 20.1b
AD+SP (21.600 U/Kg bw) 633.1 ± 13.0b
AD+NK (360 Fu/Kg bw) 682.2 ± 12.8b
AD+NK (720 Fu/Kg bw) 686.3 ± 22.3b
NK: nattokinase; SP: serrapeptase; AD: Alzheimer’s disease.
aSignificant change at p < 0.05 in comparison with the negative control group.
bSignificant change at p < 0.05 in comparison with the AD group.
Table 3 showed the effect of treatment with SP or NK on brain BDNF, TGF-β and IGF-1 levels in AD group. The untreated AD group showed significant decrease in brain BDNF and IGF-1 levels in concomitant with significant increase in brain TGF-β level in comparison with the negative control group. On the other hand, treatment with low or high dose of SP or NK caused significant increase in brain BDNF and IGF-1 levels associated with a significant decrease in brain TGF-β level in comparison with the untreated AD group.
Table 3. Effect of treatment with SP and NK on brain BDNF, TGF-β and IGF-1 levels in the model of ADa
Parameters Groups BDNF (pg/mg protein) TGF-β (pg/mg protein) IGF-1 (ng/mg protein)
Negative control 88.2 ± 2.3 626.7 ± 3.4 13.2 ± 0.6
AD group (positive control) 42.3 ± 0.6a 1046.7 ± 11.8a 9.5 ± 0.2a
AD + SP (10.800 U/Kg bw) 65.7 ± 3.3b 860.9 ± 35.3b 11.0 ± 0.2b
AD + SP (21.600 U/Kg bw) 72.5 ± 0.8b,c 830.0 ± 17.8b 11.3 ± 0.2b
AD + NK (360 Fu/Kg bw) 60.1 ± 0.8b,c,d 875.0 ± 17.3b 10.7 ± 0.2b
AD + NK (720 Fu/Kg bw) 57.9 ± 0.9b,c,d 890.0 ± 20.5b,d 10.5 ± 0.1b
NK: nattokinase; SP: serrapeptase; AD: Alzheimer’s disease.
aSignificant change at p < 0.05 in comparison with the negative control group.
bSignificant change at p < 0.05 in comparison with AD group.
cSignificant change at p < 0.05 in comparison with AD group treated with low dose of SP.
dSignificant change at p < 0.05 in comparison with AD group treated with high dose of SP.
Noteworthy, treatment with a high dose of SP caused significant increase in brain BDNF level in comparison with the group of rats treated with low dose of SP. On the other hand, treatment with low or high dose of NK produced significant decrease in brain BDNF level in comparison with low or high dose of SP. Meanwhile, the group of rats treated with high dose of NK showed significant increase in brain TGF-β level in comparison with the group of rats treated with high dose of SP.
The data in Table 4 showed the effect of treatment with SP and NK on brain Fas and IL-6 levels in the model of AD. The untreated AD group showed significant increase in brain Fas and IL-6 levels in comparison with the negative control group. On the contrary, treatment with low or high dose of SP or NK caused significant decrease in brain Fas level in comparison with the untreated AD group. Also, treatment with high dose of SP produced significant decrease in brain IL-6 level in comparison with the untreated AD group. Noteworthy, treatment with low dose of NK showed significant elevation in brain Fas level when compared with the group of rats treated with high dose of SP. Meanwhile, treatment with high dose of NK caused significant increase in brain Fas level when compared with the groups of AD treated with low or high dose of SP as well as low dose of NK.
Table 4. Effect of treatment with SP and NK on brain Fas and IL-6 levels in the model of ADa
Parameters Groups Fas (pg/mg protein) IL-6 (pg/mg protein)
Negative control 28.8 ± 0.4 26.6 ± 1.4
AD group (positive control) 65.9 ± 2.9a 35.9 ± 0.3a
AD + SP (10.800 U/Kg bw) 45.6 ± 1.6b 33.9 ± 3.3
AD + SP (21.600 U/Kg bw) 40.7 ± 3.6b 30.0 ± 2.0b
AD + NK (360 Fu/Kg bw) 48.1 ± 1.4b,d 32.7 ± 0.9
AD + NK (720 Fu/Kg bw) 58.8 ± 2.4b,c,d,e 34.5 ± 0.4
NK: nattokinase; SP: serrapeptase; AD: Alzheimer’s disease.
aSignificant change at p < 0.05 in comparison with the negative control group.
bSignificant change at p < 0.05 in comparison with the AD group.
cSignificant change at p < 0.05 in comparison with AD group treated with low dose of SP.
dSignificant change at p < 0.05 in comparison with AD group treated with high dose of SP.
eSignificant change at p < 0.05 in comparison with AD group treated with low dose of NK.

Molecular genetic results

Expression of ADAM9 and ADAM10 genes

The results of the expression analysis of ADAM9 and ADAM10 genes in different studied groups are represented in Figures 1 and 2.
Figure 1. Semiquantitative RT-PCR of ADAM9 gene in brain tissue of AD group treated with SP and NK at low (a) and high (b) doses for 45 days. Superscripts with different letters within each column means significantly different (p < 0.05). RT-PCR: real time-polymerase chain reaction; ADAM9: disintegrin and metalloproteinase domain 9; SP: serrapeptase; NK: nattokinase; ADAM10: disintegrin and metalloproteinase domain 10; AD: Alzheimer’s disease.
Figure 2. Semi-quantitative RT-PCR of ADAM10 gene in brain tissue of AD group treated with SP and NK at low (a) and high (b) doses for 45 days. Superscripts with different letters within each column means significantly different (p < 0.05). RT-PCR: real time-polymerase chain reaction; SP: serrapeptase; NK: nattokinase; ADAM10: disintegrin and metalloproteinase domain 10; AD: Alzheimer’s disease.
The current results revealed that the expression level of ADAM9 gene was significantly decreased in the brain tissues of AD group in comparison with the negative control group (Figure 1). In comparison with the expression level of ADAM9 in the brain tissue of AD group, low doses of SP and NK did not affect the expression level of ADAM9 gene in brain tissue of the treated AD group significantly, while the expression level of ADAM9 gene in the brain tissue of these groups was still higher than that in the untreated AD group. Using high doses of SP or NK increased the expression level of ADAM9 in the brain tissue of the treated AD group significantly when compared with that of the untreated AD group. Significant increase in the expression level of ADAM9 gene in the brain tissue of AD group treated with high dose of NK when compared with that in AD group treated with the low dose of NK as well as low or high dose of SP (Figure 1).
Regarding the expression level of ADAM10 gene in the brain tissue, the results of the present study revealed that the expression level of ADAM10 gene was significantly decreased in AD group when compared with the negative control group (Figure 2). Low dose of SP did not affect the expression level of ADAM10 gene in the brain tissue of the treated AD group significantly when compared with that in the untreated AD group, although the expression level of ADAM10 gene in the brain tissue of this group was still higher than that in the untreated AD group (Figure 2). However, the treatment of AD group with the low dose of NK was able to increase the expression level of ADAM10 gene in the brain tissue significantly when compared with that in the untreated AD group. On the other hand, using a high dose of SP or NK increased the expression level of ADAM10 in the brain tissue of the treated AD group significantly when compared with that in the untreated AD group. Similarly, treatment of AD group with low dose of SP produced significant decrease in the expression level of ADAM10 gene in the brain tissue when compared with that in AD group treated with high dose of NK, low dose of NK as well as high dose of NK (Figure 2).

Histological results

Our histological study showed that there is no histopathological alteration observed in the meninges, cerebral cortex and cerebrum (Figure 3(a)), hippocampus (Figure3(b)), cerebellum (Figure 3(c)) and medulla oblongata (Figure 3(d)) of the brain of healthy control rats (negative control group).
Figure 3. (a) Photomicrograph of brain section of rat in the healthy control (negative control) group showing the normal histological structure of the meninges (m) cerebral cortex (CC) and cerebrum (C). (H&E, ×40). (b) Photomicrograph of brain section of rat in the healthy control (negative control) group showing the normal histological structure of the hippocampus (hp). (H&E, ×40). (c) Photomicrograph of brain section of rat in the healthy control (negative control) group showing the normal histological structure of the cerebellum (Cr) (H&E, ×40). (d) Photomicrograph of brain section of rat in the healthy control (negative control) group showing the normal histological structure of the medulla oblongata (mo). (H&E, ×40). H&E: hematoxylin and eosin stain.
Oral administration of AlCl3 in a dose of 17 mg/kg bw for 45 days induced AD-like pathology model (AD group). This event is confirmed by our histological investigation of brain tissues of rats in this group (Figures 4(a) to (g)). These figures showed the appearance of focal gliosis in the cerebral cortex (Figure 4(a)) associated with neuronal degeneration in the hippocampus (Figure 4(b)). The hippocampus also showed focal hyalinosis with cellular (Figure 4(c)) as well as a cellular amyloid plaques formation (Figure 4(d)). Encephalomlacia was detected in the cerebral matrix with the degeneration of the surrounding neurons (Figure 4(e)), while the blood vessels showed perivascular cuffing (Figure 4(f)). Also, there was degeneration in the Purkenje cells of the cerebellum (Figure 4(g)).
Figure 4. (a) Photomicrograph of brain section of rat (AD group) showing focal gliosis in cerebral cortex (g) (H&E, ×64). (b) Photomicrograph of brain section of rat (AD group) showing neuronal degeneration in the hippocampus (arrow) (H&E, ×80). (c) Photomicrograph of brain section of rat (AD group) showing focal hyalenosis with cellular Plaque formation (h) in hippocampus (H&E, ×80). (d) Photomicrograph of brain section of rat (AD group) showing hyalenosis with a cellular plaque formation and encephalomalacia (h) (H&E, ×64). (e) Photomicrograph of brain section of rat (AD group) showing encephalomalacia and neuronal degeneration (C) (H&E x 160). (f) Photomicrograph of brain section of rat (AD group) showing pesivascular caffing (C) (H&E ×160). (g) Photomicrograph of brain section of rat (AD group) showing degeneration in purkenji cells (arrow) in cerebellum (H&E, ×160). AD: Alzheimer’s disease; H&E: hematoxylin and eosin stain.
Treatment of AD group rats with the low dose of SP (10.8 U/kg bw) for 45 days resulted in an appreciable improvement in the histological feature of the different brain areas in concomitant with the disappearance of amyloid plaques in the hippocampus. There was only focal gliosis in the cerebrum (Figure 5(a)). Treatment of AD group with the high dose of SP (21.6 U/kg bw) led to a complete dissolution of amyloid plaques in the hippocampus. Only, the presence of focal gliosis (Figure 5(b)) and perivascular cuffing (Figure 5(c)) was observed in the cerebrum.
Figure 5. (a) Photomicrograph of brain section of rat in AD group treated with low dose of SP (10.8 U/kg bw) daily for 45 days showing focal gliosis in cerebrum (g) (H&E, ×40). (b) Photomicrograph of brain section of rat in AD group treated with high dose of SP (21.6 U/kg bw) daily for 45 days showing focal gliosis in cerebrum (g) (H&E, ×40). (c) Photomicrograph of brain section of rat in AD group treated with high dose of SP (21.6 U/kg bw) daily for 45 days showing pesivascular caffing (arrow) (H&E, ×40). AD: Alzheimer’s disease; H&E: hematoxylin and eosin stain; SP: serrapeptase.
Treatment of AD group with a low dose of NK (360 Fu/ kg bw) for 45 days revealed an obvious improvement in the histology of different brain areas associated with the lysis of amyloid plaques in the hippocampus. Focal gliosis was observed only in the striatum of the cerebrum (Figure 6(a)). Treatment of AD group with a high dose of NK (720 Fu/kg bw) resulted in the disappearance of amyloid plaques in the hippocampus. The cerebrum showed focal gliosis (Figure 6(b)) as well as diffuse gliosis in the striatum of the cerebrum (Figure 6(c)).
Figure 6. (a) Photomicrograph of brain section of rat in AD group treated with low dose of NK (360 Fu/kg bw) daily for 45 days showing focal gliosis in striatum of cerebrum (g) (H&E, ×40). (b) Photomicrograph of brain section of rat in AD group treated with high dose of NK (720 Fu/kg bw) daily for 45 days showing focal gliosis in cerebrum (g) (H&E, ×40). (c) Photomicrograph of brain section of rat in AD group treated with high dose of NK (720 Fu/kg bw) daily for 45 days showing diffuse gliosis in striatum of cerebrum (arrow) (H&E, ×64). AD: Alzheimer’s disease; H&E: hematoxylin and eosin stain; NK: nattokinase.

Discussion

Several proteins can form amyloid fibrils in vivo, which are related to various diseases, such as AD. Enhancing amyloid clearance is one of the targets of the therapy of these amyloid-related diseases.3 In this study, we investigate whether the proteolytic enzymes, namely SP and NK, could ameliorate certain factors involved in AD pathophysiology in an experimental rat model in an attempt to explore new modalities for the management of AD.
Protoelytic enzymes are a group of enzymes that break the long chain-like molecules of proteins into shorter fragments (peptides) and eventually into their components called amino acids.33
The current study demonstrated that the AlCl3 administration (AD-like pathology model) revealed a significant increase in brain acetylcholinesterase (AchE) activity. This result coincides with that of Zhang et al.34 The two suggested mechanisms for aluminium-induced stimulation of AchE activity in the brain are: (1) aluminium can induce caspase-1 activation and IL-1β secretion.35 IL-1β has been found to promote the activity and expression of AchE both in cell cultures and in vivo.36 (2) aluminium can augment the accumulation of insoluble Aβ protein.37 Aβ induced elevation in the AchE activity through the induction of lipid peroxidation in neuronal membranes due to the production of hydrogen peroxide (H2O2).38 H2O2 may have a direct action on the AchE enzyme as it acts as a modulator (may be allosteric) in the activity of functionally important proteins, receptors and enzymes.39 Based on these findings, aluminium’s action on AchE activity may be related to the involvement of aluminium in the aetiology of AD pathological process,40 as the impairment of cholinergic neurotransmission became a well established fact in AD.41
In the present study, the induction of AD-like pathology in rats via AlCl3 supplementation resulted in a significant decrease in brain BDNF level. Inflammatory stimulation strongly decreases the generation and release of the neurotrophic factors, which further contributes to neurodegeneration.42 Aluminium has been found to induce the inflammatory genes leading to the production of a number of proinflammatory cytokines.43 Parallel to the increasing generation of these cytokines, a dramatic decrease in the nerve growth factor and BDNF was demonstrated after aluminium intoxication.44 The second possible mechanism by which aluminium could decrease brain BDNF in the present study is related to aluminium-induced Aβ formation in the brain. Aβ has been shown to reduce BDNF content and function45 via imparing BDNF retrograde transport. Thus, Aβ could reduce BDNF signalling and this may underlie the synaptic dysfunction observed in AD patients.46 In view of neuroprotective effects of BDNF, the demonstrated decrease in BDNF in AD patients may contribute to the development of this neurodegenerative disease due to a lack of neurotrophic support.47 These observations assess the contribution of aluminium in the pathophysiology of AD.
The induction of AD-like pathology in rats by AlCl3 administration in the present study produced a significant elevation in brain TGF-β level. This finding could be explained by the stimulatory effect of aluminium on Aβ deposition in the brain, as it has been suggested that Aβ could induce a remarkable inflammatory cascade leading to the production of inflammatory cytokines.48 Also, the experimental studies on microglial cells stimulated by 1–42 peptide of Aβ showed high transcription level of many proinflammatory cytokine genes such as Tumor necrosis factor-alpha (TNF-α), monocyte chemoattarctant protein-1 (MCP-1), IL-8 and TGF-β.49,50 These observations are in consistent with other reports that showed elevations of TGF-β expression and immunoreactivity in AD patients.51 Our findings are greatly supported by the study of Salins et al.52 who stated that TGF-β level was markedly upregulated in cortical brain regions of mouse model of familial AD.
Our results showed a significant decrease in brain IGF-1 level in AD-like pathology model due to aluminium administration. On the basis of decreased IGF-1 concentrations in AD, some authors have suggested that disrupted IGF-1 input into the brain may be involved in the pathogenesis of amyloidosis and that changed the IGF-1 signalling may potentially lead to amyloidosis.53 IGF-1 resistance at the blood–brain barrier is a pathogenic event in AD, and the local alterations in insulin like growth factor binding proteins (IGFBPs) may lead to a loss of IGF-1 input at the blood–brain barriers in AD.54 Moreover, as the increased levels of oxidative stress are associated with the aging process,55 and also impair neuronal IGF-1 signalling,56 oxidative stress may constitute a mechanism for IGF-1 resistance in the aging brain. This mechanism could also involve in our AD-like pathology model as aluminium is a well known pro-oxidant that induces oxidative stress in the brain tissue57 leading to IGF-1 resistance in AD brain.
Significant increase in brain Fas level has been detected after 45 days of AlCl3 administration to induce AD-like pathology model in the current study. A number of studies suggested a possible connection between oxidative stress and increases in Fas/FasL expression in brain astrocytes, microglia and neurons.58–60 Moreover, Fas and FasL have been reported to participate in Aβ-induced neuronal death.61 Morishima et al.62 provided evidence that Aβ induces FasL expression in a Jun N-terminal kinase (JNK3)-dependent manner. In agreement with our results Choi et al.63 reported that Fas and FasL are elevated in the compromised AD brains.
The present findings indicated that our AD-like pathology model showed a significant increase in brain IL-6 level. It has been assumed that Aβ induced by aluminium administration activates microglia and astrocytes upregulating cytokines production including IL-6.48 Also, Aβ could induce IL-6 expression in several types of brain cells.64,65 Furthermore, IL-6 enhances neuronal damage induced by Aβ.66 The destructive processes including neurodegneration gliosis and progressive neurological diseases are mediated by the overexpression of many cytokines including IL-6.67 Apelt and Schliebs68 reported that in patients with AD, IL-6 is increased locally around amyloid plaques.
AD is characterized by the excessive deposition of amyloid β-peptides (Aβ peptides) in the brain. In the non-amyloidogenic pathway, the amyloid precursor protein (APP) is cleaved by the α-secretase within the Aβ peptide sequence. Proteinases of the ADAM family (a disintegrin and metalloproteinase) are the main candidates as physiologically relevant α-secretases.69
Three members of the ADAM family, ADAM9,ADAM10 and ADAM17, can act as α-secretases in various cell lines.70,71ADAM10 can cleave APP-derived peptides at the main α-secretase cleavage site between the positions 16 and 17 of the Aβ region and it is expressed in mouse and human brain.72,73
In the present study, a significant decrease in expression levels of ADAM9 and ADAM10 genes was demonstrated in AlCl3-administered rats, which further confirmed the implication of aluminium in the pathogenesis of AD. This finding indicates that aluminium could promote the amyloidogenic pathway in the brain that results in Aβ deposition as shown in our histological study (Figures 4(a) to (g)).
The data in the present work revealed that the treatment of AD group with either SP or NK resulted in significant modulation in the different studied biochemical parameters. The detected positive effects of these enzymes could be attributed, at least in part, to the ability of SP74 and NK75 to cross the blood–brain barrier.
The proposed mechanisms for the beneficial effects of SP and/or NK may be related to the ability of SP to induce the degradation of insoluble proteins.10 Similarly, NK possesses high amyloid-degrading ability, which suggests the usefulness of this enzyme in the treatment of amyloid-related diseases.3 Thus, these enzymes might dissolve Aβ protein that accumulates in the brain due to aluminium neurotoxicity. This explanation was well documented by our histological findings (Figures 5(a) and 6(c)). As mentioned above, Aβ plays an important role in the activation of AchE activity in the brain besides its reducing effect on brain BDNF content. Therefore, the degradation of Aβ by these enzymes leads to the inhibition of brain AchE activity and restoration of BDNF brain level. Moreover, the dissolution of Aβ by SP and/or NK enzymes results in the blocking of the inflammatory cascade and preventing the production of the proinflammatory cytokines such as TGF-β and IL-6 in the brain. Also, the elimination of Aβ deposits helps in correcting the disruption of brain IGF-1 level and managing the process of apoptosis and neuronal death due to the suppressing of Fas expression and in turn its level in the brain.
SP has been found to have anti-inflammatory effect9,76 and the efficacy of SP in the treatment of a number of inflammatory conditions has been reported.11,12 This property of SP represents an additional mechanism by which SP could correct the activity of brain AchE and the levels of BDNF, TGF-β and IL-6 in the brain.
SP and NK are belonging to proteolytic enzymes family. These enzymes have been reported to have free radical-scavenging property,77 which enables these enzymes to reduce reactive oxygen species accumulation in the brain. By this way, both SP and NK could elevate IGF-1 and suppress Fas levels in the brain.
Regarding the effect of SP and/or NK on the expression levels of ADAM9 and ADAM10 genes in the brain tissue, our results revealed that the high doses of these enzymes could increase the expression levels of ADAM9 and ADAM10 genes. Also, the low dose of NK could elevate the expression level of ADAM10 gene in the brain tissue of the treated animals. These results indicate that these enzymes may have the ability to shift the amyloidogenic pathway to the non-amyloidogenic one via increasing the expression level of ADAM9 and ADAM10 genes in the brain. To the best of the author’s knowledge, this is the first published study that highlighted the efficacy of SP and NK in alleviating the generation of Aβ in the brain via promoting the activity of α-secretase-like action.
Several studies investigating the systemic use of SP10,12,78 and NK79 have demonstrated no adverse effects. In the present study, the lack of a dose dependence may confirm the safety of these enzymes as they are recommended as dietary supplements.
In conclusion, the results of the present work support our hypothesis that the oral administration of SP or NK would have beneficial effects against AD. Thus, they may represent good remedies for the management of AD via their proteolytic activity, antioxidant capacity and anti-amyloidogenic effect.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

1. Eichhoff G, Garaschuk O. Two-photon imaging of neural networks in a mouse model of Alzheimer's disease. Cold Spring Harb Protoc 2011; 2011(10): 1206–1216.
Crossref
PubMed
Google Scholar
2. Voisin T, Vellas B. Diagnosis and treatment of patients with severe Alzheimer's disease. Drug Aging 2009; 26: 135–144.
Crossref
PubMed
Google Scholar
3. Hsu RL, Lee KT, Wang JH, Lee LY, Chen RP. Amyloid-degrading ability of nattokinase from Bacillus subtilis natto. J Agric Food Chem. 2009; 57: 503–508.
Crossref
PubMed
Google Scholar
4. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. Mechanism of amyloid removal in pateints with Alzheimer disease treated with gantenerumab. Arch Neurol 2012; 69: 198–207.
Crossref
PubMed
Google Scholar
5. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999; 68: 1015–1068.
Crossref
PubMed
ISI
Google Scholar
6. Wang Y, Luo W, Reiser G. Trypsin and trypsin-like proteases in the brain: proteolysis and cellular functions. Cell Mol Life Sci 2008; 65: 237–252.
Crossref
PubMed
Google Scholar
7. Anfinsen CR. Principles that govern the folding of protein chains. Science 1973; 181: 223–230.
Crossref
PubMed
ISI
Google Scholar
8. Thomas PJ, Qu BH, Pedersen PL. Defective protein folding as a basis of human disease. Trends Biochem Sci 1995; 20: 456–459.
Crossref
PubMed
ISI
Google Scholar
9. Mazzone A, Catalani M, Costanzo M, Drusian A, Mandoli A, Russo S, et al. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind randomized trial versus placebo. Int Med Res 1990; 18: 379–388.
Crossref
PubMed
Google Scholar
10. Klein G, Kullich W. Short-term treatment of painful osteoarthritis of the knee with oral enzymes: randomised, doubleblind study versus Diclofenac. Clin Drug Invest 2000; 19: 15–23.
Crossref
Google Scholar
11. Panagariya A, Sharma AK. A preliminary trial of serratiopeptidase in patients with carpal tunnel syndrome. Assoc Physicians India 1999; 47: 1170–1172.
PubMed
Google Scholar
12. Nakamura S, Hashimoto Y, Mikami M, Yamanaka E, Soma T, Hino M, et al. Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease. Respirology 2003; 8: 316–320.
Crossref
PubMed
Google Scholar
13. Tai MW, Sweet BV. Nattokinase for prevention of thrombosis. Am J Health Syst Pharm 2006; 63: 1121–1123.
Crossref
PubMed
Google Scholar
14. Sumi H, Hamada H, Tsushima H, Mihara H, Muraki H. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia 1987; 43: 1110–1111.
Crossref
PubMed
Google Scholar
15. Fujita MH, Ito KY and Nishimuro S. characterization of nattokinase degraded products from human fibrinogen or cross-linked fibrin. Fibrinolysis 1995; 9: 157–164.
Crossref
Google Scholar
16. Urano T, Ihara H, Umemura K, Suzuki Y, Oike M, Akita S, et al. The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis cleaves and inactivates plasminogen activator inhibitor type 1. Biol Chem 2001; 276: 24690–24696.
Crossref
Google Scholar
17. Chang CT, Fan MH, Kuo FC, Sung HY. Potent fibrinolytic enzyme from a mutant of Bacillus subtilis IMR-NK1. Agric Food Chem 2000; 48: 3210–3216.
Crossref
PubMed
Google Scholar
18. Paget GE, Barnes JM. Evaluation of drug activities of pharmacometrics. London, UK: Academic Press, 1964, p. 134.
Google Scholar
19. Krasovskii GN, Vasukovich LY, Chariev OG. Experimental study of biological effects of leads and aluminium following oral administration. Environ Health Perspect 1979; 30: 47–51.
PubMed
Google Scholar
20. Tsakiris S, Schulpis KH, Marinou K, Behrakis P. Protective effect of L-cysteine and glutathione on the modulated suckling rat’s brain Na+, K+ ATPase and Mg2+ ATPase activities induced by the in vitro galactosaemia. Pharmacol Rse 2004; 49: 475–479.
Crossref
PubMed
Google Scholar
21. Young DS. Effect of drugs on clinical lab test, 5th ed. Washington, DC: AACC press, 2000.
Google Scholar
22. Barde YA. The nerve growth factor family. Progr Growth Factor Res 1990; 2: 237–248.
Crossref
PubMed
Google Scholar
23. Kropf J, Schurek JO, Wollner A, Gressner AM. Methodological aspects of the immunological measurement of transforming growth factor-beta 1 (TGF-β1) in blood. Assay development and comparison. Clin Chem 1997; 43: 1965–1974.
Crossref
PubMed
Google Scholar
24. Lewitt MS, Saunders H, Baxter RC. Bioavailability of insulin-like growth factors (IGFs) in rats determined by the molecular distribution of human IGF-binding protein-3. Endocrinology 1993; 133: 1797–1802.
Crossref
PubMed
Google Scholar
25. Iio S, Hayashi N, Mita E, Ueda K, Mochizuki K, Hiramatsu N, et al. Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol 1998; 29: 517–523.
Crossref
PubMed
ISI
Google Scholar
26. Bauer J, Herrmann F. Interleukin-6 in clinical medicine. Ann Hematol 1991; 62: 203–210.
Crossref
PubMed
Google Scholar
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol 1951; 193: 265–275.
Google Scholar
28. Karthikeyan K, Bai BR, Devaraj SN. Cardioprotective effect of grape seed proanthocyanidins on isoproterenol-induced myocardial injury in rats. Int J Cardiol 2007; 115: 326–333.
Crossref
PubMed
Google Scholar
29. El-Makawy AI, Girgis SM, Khalil WK. Developmental and genetic toxicity of stannous chloride in mouse dams and fetuses. Mutat Res. 2008; 657: 105–110.
Crossref
PubMed
Google Scholar
30. Ali FKH, El-Shafai SA, Samhan FA, Khalil WKB. Effect of water pollution on expression of immune response genes of Solea aegyptiaca in lake Qarun. Afr J Biotechnol 2008; 7: 1418–1425.
Google Scholar
31. Banchroft JD, Stevens A, Turner DR. Theory and practice and practice of histoloical techniques. 4th ed. New York, London, San Francisco, Tokyo: Churchill Livingstone, 1996
Google Scholar
32. Armitage P, Berry G. Comparison of several groups. Statistical method in medical research. 2th ed. Oxford, UK: Blackwell Science Ltd, 1987, pp. 186–213.
Google Scholar
33. Puente XS, Sanchez LM, Overall CM, Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 2003; 4: 544–558.
Crossref
PubMed
ISI
Google Scholar
34. Zhang J, Yang JQ, He BC, Zhou QX, Yu HR, Tang Y, et al. Berberine and total base from rhizoma coptis chinensis attenuate brain injury in an aluminum-induced rat model of neurodegenerative disease. Saud Med 2009; 30: 760–766.
PubMed
Google Scholar
35. Franchi L, Núñez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 2008; 38(8): 2085–2089.
Crossref
PubMed
ISI
Google Scholar
36. Li Y, Liu L, Kang J, Sheng JG, Barger SW, Mark RE, et al. Neuronal glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci 2000; 20: 149–155.
Crossref
PubMed
Google Scholar
37. Nayak P. Aluminum impacts and disease. Env Res 2002; 89: 111–115.
Crossref
Google Scholar
38. Melo JB, Agostinho P, Oliveira CR. Involvement of oxidative stress in the enhancement of acetylcholinesterase activity-induced by amyloid-beta peptide. Neurosci Res 2003; 45: 117–127.
Crossref
PubMed
Google Scholar
39. Kamster A, Segal M. Hydrogen peroxide as a diffusible signal molecule in synaptic plasticity. Mol Neurobiol 2004; 29: 167–178.
Crossref
PubMed
Google Scholar
40. Kaizer RR, Correa MC, Gris LRS, Da Rosa CS, Bohrer D, Morsch VM, et al. Effect of long term exposure to aluminum on the acetylcholinesterase activity in the central nervous system and erythrocytes. Neurochem Res 2008; 33: 2294–2301.
Crossref
PubMed
Google Scholar
41. Zivin M, Pregelj P. Prolonged treatment with donepezil increases acetylcholinesterase expression in the central nervous system. Psychiatr Danub 2008; 20: 168–173.
PubMed
Google Scholar
42. Nagatsu T, Sawada M. Inflammatory process in Parkinson’s disease: role for cytokines. Curr Pharmacol Des 2005; 11: 999–1016.
Crossref
PubMed
Google Scholar
43. Lukiw WJ, Percy ME, Kruck TP. Nanomolar aluminum induces proinflammatory and proapoptotic gene expression in human brain cells in primary culture. J Inorg Biochem 2005; 99: 1895–1898.
Crossref
PubMed
Google Scholar
44. Viviani B, Corsini E, Galli CL, Padovani A, Ciusani E, Marinovich M. Dying neural cells activate glia through the release of a protease product. Glia 2000; 32: 84–90.
Crossref
PubMed
Google Scholar
45. Cotman CW. The role of neurotrophins in brain aging. Neurochem Res 2005; 30: 877–881.
Crossref
PubMed
Google Scholar
46. Poon WW, Blurton-Jones M, Tu CH, Feinberg LM, Chabrier MA, Harris JW, et al. Amyloid-β impairs axonal BDNF retrograde trafficking. Neurobiol Aging 2009; 89: 1–13.
Google Scholar
47. Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, et al. BDNF serum and CSF concentrations in Alzheimer’s disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res 2007; 41: 387–394.
Crossref
PubMed
Google Scholar
48. Motta M, Imbesi R, Di Rosa M, Stivala F, Malaguarnera L. Altered plasma cytokine levels in Alzheimer’s disease: Correlation with the disease progression. Immunol Lett 2007; 114: 46–51.
Crossref
PubMed
Google Scholar
49.. Walzer DG, Lih-Fen L, Beach TG. Gene expression profiling of amyloid beta peptide stimulated human post-mortem brain microglia. Neurobiol Aging 2001; 22: 957–966.
Crossref
PubMed
Google Scholar
50. Wang G, Zhang Y, Chen B, Cheng J. Preliminary studies on Alzheimer’s disease using cDNA microarrays. Mech Ageing Dev 2003; 124: 115–124.
Crossref
PubMed
Google Scholar
51. Lacombe P, Mathews PM, Schmidt SD, Breidert T, Heneka MT, Landreth GE, et al. Effect of anti-inflammatory agents on transforming growth factor beta overexpressing mouse brains: a model revised. J Neuroinflamm 2004; 1: 1–11.
Crossref
PubMed
Google Scholar
52. Salins P, He Y, Olson K, Glazner G, Kashour T, Amara F. TGF-beta1 is increased in a transgenic mouse model of familial Alzheimer’s disease and causes neuronal apoptosis. Neurosci Lett 2008; 430: 81–86.
Crossref
PubMed
Google Scholar
53. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 2002; 8: 1390–1397.
Crossref
PubMed
Google Scholar
54. De la Monte SM, Wands JR. Alzheimer-associated neuronal thread protein mediated cell death is linked to impaired insulin signaling. J Alzheimer Dis 2004; 6: 231–234.
Crossref
PubMed
Google Scholar
55. Droge W. Oxidative stress and aging. Adv Exp Med Biol 2003; 543: 191–200.
Crossref
PubMed
ISI
Google Scholar
56. Davila D, Torres-Aleman I. Neuronal death by oxidative stress involves activation of FOXO3 through a two-arm pathway that activates stress kinases and attenuates insulin-like growth factor I signaling. Mol Biol Cell 2008; 19: 2014–2025.
Crossref
PubMed
Google Scholar
57. Kumar V, Bal A, Gill KD. Susceptibility of mitochondrial superoxide dismutase to aluminium induced oxidative damage. Toxicology 2009; 255: 117–123.
Crossref
PubMed
Google Scholar
58. Vogt M, Bauer MK, Ferrari D, Schulze-Osthoff K. Oxidative stress and hypoxia/reoxygenation trigger CD95 (APO-/Fas) ligand expression in microglial cells. FEBS Lett 1998; 429: 67–72.
Crossref
PubMed
Google Scholar
59. de la Monte SM, Neely TR, Cannon J, Wands JR. Oxidative stress and hypoxia-like injury cause Alzheimer-type molecular abnormalities in central nervous system neurons. Cell Mol Life Sci 2000; 57: 1471–1481.
Crossref
PubMed
Google Scholar
60. Kwon D, Choi C, Lee J, Kim KO, Kim JD, Kim SJ, Choi IH. Hydrogen peroxide triggers the expression of Fas/FasL in astrocytoma cell lines and augments apoptosis. J Neuroimmunol 2001; 113(1): 1–9.
Crossref
PubMed
Google Scholar
61. Millet P, Lages C, Haïk S, Nowak E, Allemand I, Granotier C, et al. Amyloid-β peptide triggers Fas-independent apoptosis and differentiation of neural progenitor cells. Neurobiol Dis 2005; 19(12): 57–65.
Crossref
PubMed
Google Scholar
62. Morishima Y, Gotoh Y, Zieg J, Barrett T, Takano H, Flavell R, et al. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 2001; 21: 7551–7560.
Crossref
PubMed
Google Scholar
63. Choi C, Etty N. Benveniste. Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res Rev 2004; 44: 65–81.
Crossref
PubMed
Google Scholar
64. Jana M, Palencia CA, Pahan K. Fibrillar amyloid-beta peptides activate microglia via TLR2: implications for Alzheimer's disease. J Immunol 2008; 181: 7254–7262.
Crossref
PubMed
Google Scholar
65. Vukic V, Callaghan D, Walker D, Lue LF, Liu QY, Couraud PO, et al. Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer’s brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis 2009; 34: 95–106.
Crossref
PubMed
ISI
Google Scholar
66. Qiu Z, Gruol DL. Interleukin-6, beta-amyloid peptide and NMDA interactions in rat cortical neurons. J Neuroimmunol 2003; 139: 51–57.
Crossref
PubMed
Google Scholar
67. Lee Y, Choi I, Park M, Lee Y, Song J, Kim Y, et al. 4-O-Methylhonokiol attenuates memory impairment in presenilin 2 mutant mice through reduction of oxidative damage and inactivation of astrocytes and the ERK pathway. Free Radic Biol Med 2011; 50: 66–77.
Crossref
PubMed
Google Scholar
68. Apelt J, Schliebs R. Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res 2001; 894: 21–30.
Crossref
PubMed
ISI
Google Scholar
69. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. Clin Invest 2004; 113: 1456–1464.
Crossref
Google Scholar
70. Koike H, Tomioka S, Sorimachi H, Saido TC, Maruyama K, Okuyama A, Fujisawa-Sehara A, et al. Membrane-anchored metalloprotease MDC9 has an α-secretase activity responsible for processing the amyloid precursor protein. Biochem 1999; 343: 371–375.
Crossref
Google Scholar
71. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, et al. Constitutive and regulated α-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci 1999; 96: 3922–3927.
Crossref
PubMed
Google Scholar
72. Marcinkiewicz M, Seidah NG. Coordinated expression of β-amyloid precursor protein and the putative β-secretase BACE and α-secretase ADAM10 in mouse and human brain. Neurochem 2000; 75: 2133–2143.
Crossref
PubMed
Google Scholar
73.. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc Natl Acad Sci USA 2001; 98: 5815–5820.
Crossref
PubMed
Google Scholar
74. Redfer R. The ‘miracle’ enzyme™ is serrapeptase, the 2nd gift from silkworms giving the answer to pain, inflammation and clear arteries!. Hartford, UK: Naturally Healthy publications, 2006, p. 11.
Google Scholar
75.. Suzuki Y, Kondo K, Matsumoto Y, Zhao BQ, Otsuguro K, Maeda T, et al. Dietary supplementation of fermented soybean, natto, suppresses intimal thickening and modulates the lysis of mural thrombi after endothelial injury in rat. femoral artery. Life Sci 2003; 73: 1289–1298.
Crossref
PubMed
Google Scholar
76. Al-Khateeb TH, Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. Int J Oral Maxillofac Surg 2008; 37: 264–268.
Crossref
PubMed
Google Scholar
77. Davies K. Intracellular proteolytic systems may function as secondary antioxidant defenses: an hypothesis. J Free Radic Biol Med 1986; 2(3): 155–173.
Crossref
PubMed
Google Scholar
78. Mecikoglu M, Saygi B, Yildirim Y, Karadag Saygi E, Ramadan SS, Esemenli T. The effect of proteolytic enzyme serratiopeptidase in the treatment of experimental implant-related infection. J Bone Joint Surg Am 2006; 88: 1208–1214.
Crossref
PubMed
ISI
Google Scholar
79. Hsia CH, Shen MC, Lin JS, Wen YK, Hwang KL, Cham TM, et al. Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects. Nutr Res 2009; 29: 190–196.
Crossref
PubMed
Google Scholar

Cite article

Cite article

Cite article

OR

Download to reference manager

If you have citation software installed, you can download article citation data to the citation manager of your choice

Share options

Share

Share this article

Share with email
EMAIL ARTICLE LINK
Share on social media

Share access to this article

Sharing links are not relevant where the article is open access and not available if you do not have a subscription.

For more information view the Sage Journals article sharing page.

Information, rights and permissions

Information

Published In

Volume 32, Issue 7
Pages: 721 - 735
Article first published online: July 2, 2013
Issue published: July 2013

Keywords

  1. Alzheimer's disease
  2. proteolytic enzymes
  3. serrapeptase
  4. nattokinase
  5. rats

Rights and permissions

© The Author(s) 2013.
Request permissions for this article.
PubMed: 23821590

Authors

Affiliations

NN Fadl
Medical Physiology Department, National Research Centre, Dokki, Cairo, Egypt
View all articles by this author
HH Ahmed
Hormones Department, National Research Centre, Dokki, Cairo, Egypt
[email protected]
View all articles by this author
HF Booles
Cell Biology Department, National Research Centre, Dokki, Cairo, Egypt
View all articles by this author
AH Sayed
Hormones Department, National Research Centre, Dokki, Cairo, Egypt
View all articles by this author

Notes

Hanaa H Ahmed, Hormones Department, National Research centre, El Bohouth Street, Dokki, Cairo 12622, Egypt. Email: [email protected]

Metrics and citations

Metrics

Journals metrics

This article was published in Human & Experimental Toxicology.

VIEW ALL JOURNAL METRICS

Article usage*

Total views and downloads: 12264

*Article usage tracking started in December 2016

Articles citing this one

Receive email alerts when this article is cited

Web of Science: 50 view articles Opens in new tab

Crossref: 55

  1. Conditioned Media Therapy in Alzheimer's Disease: Current Findings and...
    Go to citation Crossref Google Scholar
  2. An up-to-date review of biomedical applications of serratiopeptidase a...
    Go to citation Crossref Google Scholar
  3. The significance of precisely regulating heme oxygenase-1 expression: ...
    Go to citation Crossref Google Scholar
  4. Development of novel natto using legumes produced in Europe
    Go to citation Crossref Google Scholar
  5. Research Progress in Nattokinase and Its Pharmacology
    Go to citation Crossref Google Scholar
  6. Centella asiatica L. Urban protects against cognitive dy...
    Go to citation Crossref Google Scholar
  7. In vitro and in silico evaluation of the serrapeptase effect on biofil...
    Go to citation Crossref Google Scholar
  8. Nattokinase: Insights into Biological Activity, Therapeutic Applicatio...
    Go to citation Crossref Google Scholar
  9. Fibrin and Fibrinolytic Enzyme Cascade in Thrombosis: Unravelling the ...
    Go to citation Crossref Google Scholar
  10. Protective effects of nattokinase against ...
    Go to citation Crossref Google Scholar
  11. Degradation of amyloid β-peptides catalyzed by nattokinase in vivo and...
    Go to citation Crossref Google Scholar
  12. Nattokinase Promotes Post-stroke Neurogenesis and Cognition Recovery v...
    Go to citation Crossref Google Scholar
  13. Germanium Dioxide Nanoparticles Mitigate Biochemical and Molecular Cha...
    Go to citation Crossref Google Scholar
  14. Serratiopeptidase Attenuates Lipopolysaccharide-Induced Vascular Infla...
    Go to citation Crossref Google Scholar
  15. Serrapeptase impairs biofilm, wall, and phospho-homeostasis of resista...
    Go to citation Crossref Google Scholar
  16. Nattokinase: Structure, applications and sources
    Go to citation Crossref Google Scholar
  17. Centella asiatica Alleviates AlCl3-induced Cognitive Impairment, Oxida...
    Go to citation Crossref Google Scholar
  18. Soy product intake and risk of incident disabling dementia: the JPHC D...
    Go to citation Crossref Google Scholar
  19. Protective role of IGF-1 and GLP-1 signaling activation in neurologica...
    Go to citation Crossref Google Scholar
  20. Production, purification, and functional properties of microbial fibri...
    Go to citation Crossref Google Scholar
  21. Nattokinase attenuates bisphenol A or gamma irradiation-mediated hepat...
    Go to citation Crossref Google Scholar
  22. Phosphocalcic metabolism and the role of vitamin D, vitamin K2, and na...
    Go to citation Crossref Google Scholar
  23. Recent Advances in Nattokinase-Enriched Fermented Soybean Foods: A Rev...
    Go to citation Crossref Google Scholar
  24. Enhanced Production Process of Recombinant Mature Serratiopeptidase in...
    Go to citation Crossref Google Scholar
  25. Biotechnology, Bioengineering and Applications of Bacillus Nattokinase
    Go to citation Crossref Google Scholar
  26. Production of fibrinolytic enzymes during food production
    Go to citation Crossref Google Scholar
  27. Aluminum inhibits non-amyloid pathways via retinoic acid receptor
    Go to citation Crossref Google Scholar
  28. Protective Effects of Nattokinase Against Microvascular Abnormalities ...
    Go to citation Crossref Google Scholar
  29. Safety assessment of subtilisin QK in rats
    Go to citation Crossref Google Scholar
  30. Fibrinolytic and ACE Inhibitory Activity of Nattokinase Extracted from...
    Go to citation Crossref Google Scholar
  31. Microbial Fibrinolytic Enzymes as Anti-Thrombotics: Production, Charac...
    Go to citation Crossref Google Scholar
  32. Changes in Functionality of Germinated and Non-Germinated Brown Rice F...
    Go to citation Crossref Google Scholar
  33. Nutraceutical Approach to Preventing Coronavirus Disease 2019 and Rela...
    Go to citation Crossref Google Scholar
  34. Serratiopeptidase, A Serine Protease Anti-Inflammatory, Fibrinolytic, ...
    Go to citation Crossref Google Scholar
  35. Data Recorded in Real Life Support the Safety of Nattokinase in Patien...
    Go to citation Crossref Google Scholar
  36. Nattokinase Attenuates Retinal Neovascularization Via Modulation of Nr...
    Go to citation Crossref Google Scholar
  37. Vascular Necrosis of the Upper Extremity After Self-Treatment for Peyr...
    Go to citation Crossref Google Scholar
  38. Importance of fermented foods on human health
    Go to citation Crossref Google Scholar
  39. Serratiopeptidase: Insights into the therapeutic applications
    Go to citation Crossref Google Scholar
  40. Nattokinase mitigated dextran sulfate sodium-induced chronic colitis b...
    Go to citation Crossref Google Scholar
  41. An Overview of ADAM9: Structure, Activation, and Regulation in Human D...
    Go to citation Crossref Google Scholar
  42. Bacillus Subtilis Delays Neurodegeneration and Behavioral Impairment i...
    Go to citation Crossref Google Scholar
  43. Exploiting Citrus aurantium seeds and their secondary metabolites in t...
    Go to citation Crossref Google Scholar
  44. Focalization of thrombosis and therapeutic perspectives: a memoir
    Go to citation Crossref Google Scholar
  45. Co-delivery of curcumin and serratiopeptidase in HeLa and MCF-7 cells ...
    Go to citation Crossref Google Scholar
  46. Nattokinase: A Promising Alternative in Prevention and Treatment of Ca...
    Go to citation Crossref Google ScholarPub Med
  47. The present and future of pharmacotherapy of Alzheimer’s disease: A co...
    Go to citation Crossref Google Scholar
  48. Production, purification, characterization, immobilization, and applic...
    Go to citation Crossref Google Scholar
  49. Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardio...
    Go to citation Crossref Google Scholar
  50. Protective effect of transient receptor potential vanilloid subtype 1 ...
    Go to citation Crossref Google Scholar
  51. Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer’s Dis...
    Go to citation Crossref Google Scholar
  52. Interactions between nattokinase and heparin/GAGs
    Go to citation Crossref Google Scholar
  53. Nattokinase: production and application
    Go to citation Crossref Google Scholar
  54. Effect of an herbal/botanical supplement on recovery from delayed onse...
    Go to citation Crossref Google Scholar
  55. Pharmacogenomics of Alzheimer’s Disease: Novel Therapeutic Strategies ...
    Go to citation Crossref Google Scholar

Figures and tables

Figures & Media

Tables

View Options

View options

PDF/ePub

View PDF/ePub

Get access

Access options

If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:

Alternatively, view purchase options below:

Purchase 24 hour online access to view and download content.

Subscribe to this journal

Access journal content via a DeepDyve subscription or find out more about this option.

Start 2 week free trial
Need help?

Also from Sage